Professor Harry Hausler, the CEO of TB HIV Care and a former technical advisor to the national Department of Health on TB/HIV, believes the main reason for this “massive” uptick in blood-borne ...
Zacks.com on MSN2h
Gilead, MRK Report Data From Investigational Combination Study for HIVGilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...
With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...
Doctors and front-line workers are watching closely as HIV rates increase significantly in Alberta.An annual Alberta Health ...
Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback